ArriVent Biopharma Rings the Opening Bell

About This Event

ArriVent Biopharma (Nasdaq: AVBP), a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, visits the Nasdaq MarketSite in Times Square. ArriVent seeks to utilize its team's deep drug development experience to maximize the potential of its lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

In honor of the occasion, Bing Yao, CEO and Chairman, rings the Opening Bell.